Figure 2
Figure 2. Distribution and outcomes based on FISH abnormalities among patients with SMM. (A) No interphase FISH abnormalities, white; standard risk: t(11;14), t(14;16), or t(14;20) or other/unknown IgH or del 13/13q, light gray; intermediate risk: trisomy without IgH translocation, dark gray; high risk: t(4;14)or del (17p), black. Solid bars, progression from SMM to MM; stippled bars, OS from SMM diagnosis. (B) Duration of time a patient lives with labels ranging from MGUS to SMM to active MM is in part related to interphase FISH. Although individuals harboring trisomies (ii) appear to progress more rapidly through their diagnosis of SMM than patients with normal FISH or non-t(4;14) translocations (i), they survive much longer than those with deletion 17p (iii) and about as long as patients with normal or non-t(4;14) translocations (i). Mo, months.

Distribution and outcomes based on FISH abnormalities among patients with SMM. (A) No interphase FISH abnormalities, white; standard risk: t(11;14), t(14;16), or t(14;20) or other/unknown IgH or del 13/13q, light gray; intermediate risk: trisomy without IgH translocation, dark gray; high risk: t(4;14)or del (17p), black. Solid bars, progression from SMM to MM; stippled bars, OS from SMM diagnosis. (B) Duration of time a patient lives with labels ranging from MGUS to SMM to active MM is in part related to interphase FISH. Although individuals harboring trisomies (ii) appear to progress more rapidly through their diagnosis of SMM than patients with normal FISH or non-t(4;14) translocations (i), they survive much longer than those with deletion 17p (iii) and about as long as patients with normal or non-t(4;14) translocations (i). Mo, months.

Close Modal

or Create an Account

Close Modal
Close Modal